ARS Pharmaceuticals, Inc.

NasdaqGM:SPRY Rapporto sulle azioni

Cap. di mercato: US$1.3b

ARS Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Rich Lowenthal

Amministratore delegato

US$10.0m

Compenso totale

Percentuale dello stipendio del CEO6.2%
Mandato del CEO2yrs
Proprietà del CEO5.8%
Durata media del management2.6yrs
Durata media del Consiglio di amministrazione3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

ARS Pharmaceuticals: Demand Curve Is Key Unknown

Nov 20

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

Sep 06

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

Jun 25

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

Mar 18
We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14
ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rich Lowenthal rispetto agli utili di ARS Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$49m

Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$10mUS$620k

-US$54m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$53m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$909kUS$75k

-US$35m

Compensazione vs Mercato: La retribuzione totale di Rich ($USD 10.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.37M ).

Compensazione vs guadagni: La retribuzione di Rich è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Rich Lowenthal (58 yo)

2yrs

Mandato

US$10,039,096

Compensazione

Mr. Richard E. Lowenthal, also known as Rich, MS, MSEL, MBA, He serves as Director, Chief Executive Officer & President at ARS Pharmaceuticals, Inc. since November 08, 2022. He served as Head of Regulatory...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Richard Lowenthal
Founder2yrsUS$10.04m5.77%
$ 76.0m
Sarina Tanimoto
Co-Founder & Chief Medical Officerno dataUS$4.79m3.51%
$ 46.2m
Alexander Fitzpatrick
Chief Legal Officer & Secretary1.8yrsUS$5.32m0.092%
$ 1.2m
Robert Bell
Co-Founder & Chief Science Officerno dataNessun dato4.34%
$ 57.1m
Kathleen Scott
Chief Financial Officer2.6yrsNessun dato0.014%
$ 178.8k
Brian Dorsey
Chief Operations Officerno dataNessun dato0.0062%
$ 81.6k
Daniel Relovsky
Senior Vice President of Marketing2.8yrsNessun datoNessun dato
Harris Kaplan
Executive Vice President of Commercial Strategy2.8yrsNessun datoNessun dato
Eric Karas
Chief Commercial Officer2.6yrsUS$618.61k0.0059%
$ 77.2k
Justin Chakma
Chief Business Officer & Secretary2yrsNessun datoNessun dato

2.6yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di SPRY è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Richard Lowenthal
Founder2yrsUS$10.04m5.77%
$ 76.0m
Phillip Schneider
Independent Directorno dataUS$261.30k0%
$ 0
Pratik Shah
Chairman of the Boardno dataUS$508.80k4.96%
$ 65.4m
Brenton L. Saunders
Director3.5yrsUS$238.80k0%
$ 0
Rajeev Dadoo
Independent Director3.3yrsUS$256.30kNessun dato
Peter Kolchinsky
Independent Director3.3yrsUS$253.80kNessun dato
Saqib Islam
Independent Director2yrsUS$250.05k0.016%
$ 206.5k
Thomas Casale
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Michael Kaliner
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Motohiro Ebisawa
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Michael Kelly
Independent Directorno dataUS$248.80k0.086%
$ 1.1m
Richard Lockey
Member of Scientific Advisory Boardno dataNessun datoNessun dato

3.3yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SPRY sono considerati esperti (durata media dell'incarico 3.3 anni).